News & Articles

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

The new line aims to provide unmatched sensitivity, resolution, speed, and flexibility of colors

Emergency scans captured images of the top of the lungs where a fluffiness known as ‘ground glass opacification’ allowed COVID-19 to be diagnosed

AstraZeneca anticipates entering clinical development in 2021

The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus

The partnership aims to co-market exosome technology as well as the joint development of new exosome based products

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs

Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes

Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis

Join us on Thursday, September 24, to learn more about new updates of the NanoDrop One platform

The agreement is part of preparations for GMP production of material for the first clinical study of CG01

Join us on Monday, September 21, to learn about assay development for high-throughput screening

New research published in Nature Immunology show strong T cell responses in patients recovered from COVID-19

CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for GAVRETO

New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus

Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections

Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021

Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method